The effectiveness of the use of metformin in breast cancer patients with metabolic syndrome

Summary. In 2005, the International Diabetes Federation (IDF) called metabolic syndrome is one of the main problems of modern medicine because it increases overall mortality. The prevalence of the metabolic syndrome has reached pandemic levels. In economically developed countries, this syndrome is manifested in 25–35% of the population of all ages, this figure increases with age and is 42–43.5% of the population older than 60 years. Cancer patients with the metabolic syndrome reported decreased sensitivity of a tumor to antineoplastic therapy system, increased incidence of postoperative complications, and decrease in overall and disease-free survival compared with patients without the metabolic syndrome. The aim of this work is to study the advisability of metformin during systemic anticancer therapy of breast cancer patients with the metabolic syndrome.